LKFT(Lakefront Biotherapeutics NV) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $276.58M | $254.02M | $260.27M | $297.72M | $1.26B |
| 毛利润 | $274.65M | $241.30M | — | $260.06M | $1.23B |
| 营业利润 | −$202.45M | −$137.99M | −$95.83M | −$203.42M | $334.00M |
| 净利润 | −$121.81M | −$229.53M | $229.84M | $80.01M | $363.26M |
| 经营现金流 | −$594.52M | −$527.04M | −$440.77M | −$345.65M | −$291.46M |
| 自由现金流 | −$658.48M | −$555.88M | −$461.07M | −$363.71M | −$306.97M |
| 摊薄每股收益 | $-1.86 | $-3.50 | $3.49 | $1.21 | $5.51 |